Chemo-Immunotherapy Plus Radiation vs Standard Treatment for Advanced Esophageal Cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with unresectable (cannot be surgically removed) stage III or IVA esophageal squamous cell carcinoma confirmed by biopsy or cell sample
- Good overall health and physical function (able to do light activities; ECOG score 0–1)
- Normal or acceptable blood counts, liver, kidney, and heart function within 2 weeks of starting the trial
- Measurable cancer that can be tracked on imaging scans
- Never had radiation to the chest or chemotherapy for esophageal cancer before
- No other active cancer diagnoses in the past 5 years, except certain treated skin or cervical cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial compares the current standard treatment (chemotherapy and radiation) with a newer approach that combines chemotherapy and immunotherapy before surgery for esophageal cancer. Participation may help determine if this new combination is more effective for you.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial compares two treatments given before surgery for esophageal cancer. One combines an immunotherapy drug (Toripalimab) with chemotherapy (nab-paclitaxel and platinum). The other uses a different standard chemotherapy regimen (DCF). The goal is to see which is better at shrinking tumors and improving outcomes for patients with resectable, locally advanced esophageal squamous cell carcinoma.
This study tests a new combination approach before surgery for esophageal cancer. You would receive a short course of radiation together with an immunotherapy drug called serplulimab and standard chemotherapy, to see if it helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.